## RO6889678

Cat. No.: HY-124364   CAS No.: 1578153-27-1   Molecular Formula: C <sub>21</sub> H <sub>20</sub> ClFN <sub>4</sub> O <sub>5</sub> S   Molecular Weight: 494.92   Target: HBV; Cytochrome P450   Pathway: Anti-infection; Metabolic Enzyme/Protease   Storage: Please store the product under the recommended conditions in the Certificate of Analysis.			
Molecular Formula: C <sub>21</sub> H <sub>20</sub> ClFN <sub>4</sub> O <sub>5</sub> S   Molecular Weight: 494.92   Target: HBV; Cytochrome P450   Pathway: Anti-infection; Metabolic Enzyme/Protease   Storage: Please store the product under the recommended conditions in the Certificate of	Cat. No.:	HY-124364	O II
Molecular Weight: 494.92   Target: HBV; Cytochrome P450   Pathway: Anti-infection; Metabolic Enzyme/Protease   Storage: Please store the product under the recommended conditions in the Certificate of	CAS No.:	1578153-27-1	о
Target: HBV; Cytochrome P450   Pathway: Anti-infection; Metabolic Enzyme/Protease   Storage: Please store the product under the recommended conditions in the Certificate of	Molecular Formula:	C <sub>21</sub> H <sub>20</sub> ClFN <sub>4</sub> O <sub>5</sub> S	
Pathway: Anti-infection; Metabolic Enzyme/Protease   Storage: Please store the product under the recommended conditions in the Certificate of	Molecular Weight:	494.92	
Storage: Please store the product under the recommended conditions in the Certificate of	Target:	HBV; Cytochrome P450	HŅ
	Pathway:	Anti-infection; Metabolic Enzyme/Protease	S N
	Storage:		

BIOLOGICAL ACTIVITY					
biological activity					
Description	RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation <sup>[1]</sup> .				
IC <sub>50</sub> & Target	СҮРЗА4				

## REFERENCES

[1]. Nicole A Kratochwil, et al. Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor. J Pharmacol Exp Ther. 2018 May;365(2):237-248.

Caution: Product has not been fully validated for medical applications. For research use only.

Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

`0´

## Product Data Sheet



Tel: 609-228-6898